Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.

[1]  T. Rabelink,et al.  Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.

[2]  J. Cohn.  What is the role of angiotensin-receptor blockade in cardiovascular protection? , 2006, American heart journal.

[3]  D. Duprez.  Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review , 2006, Journal of hypertension.

[4]  Rod Jackson,et al.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk , 2005, The Lancet.

[5]  B. Dahlöf,et al.  Surrogate markers for cardiovascular disease: structural markers. , 2004, Circulation.

[6]  Anne L. Taylor,et al.  Screening for early detection of cardiovascular disease in asymptomatic individuals. , 2003, American heart journal.

[7]  Jason D. Allen,et al.  Assessing risk for coronary heart disease: beyond Framingham. , 2003, American heart journal.

[8]  R. Schmieder,et al.  Effect of AT1 receptor blockade on endothelial function in essential hypertension. , 2003, American journal of hypertension.

[9]  R. Zimlichman,,et al.  Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. , 2002, American journal of hypertension.

[10]  E. Schiffrin,et al.  Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension , 2001, Journal of hypertension.

[11]  E. Schiffrin,et al.  Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. , 2000, Circulation.

[12]  A. Dyer,et al.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.

[13]  V. Fuster,et al.  AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Journal of the American College of Cardiology.

[14]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[15]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[16]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.